LCAOS

A Nanoscale Artificial Nose to easily detect Volatile Biomarkers at Early stages of Lung Cancer and Related Genetic Mutations

Coordinatore	TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY    more  Organization address address: TECHNION CITY - SENATE BUILDING city: HAIFA postcode: 32000 contact info Titolo: Dr. Nome: Birsan Cognome: Silvia Email: send email Telefono: +972 4 8293560 Fax: +972 4 8295672
Nazionalità Coordinatore	Israel [IL]
Totale costo	5˙405˙173 €
EC contributo	4˙140˙174 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2010-two-stage
Funding Scheme	CP-FP
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-04-01   -   2015-03-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY  Organization address address: TECHNION CITY - SENATE BUILDING city: HAIFA postcode: 32000 contact info Titolo: Dr. Nome: Birsan Cognome: Silvia Email: send email Telefono: +972 4 8293560 Fax: +972 4 8295672	IL (HAIFA)	coordinator	1˙211˙702.39
2	THE UNIVERSITY OF LIVERPOOL  Organization address address: Brownlow Hill, Foundation Building 765 city: LIVERPOOL postcode: L69 7ZX contact info Titolo: Ms. Nome: Veronica Cognome: Shaw Email: send email Telefono: +44 151 794 8722 Fax: +44 151 794 8728	UK (LIVERPOOL)	participant	654˙457.80
3	MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.  Organization address address: Hofgartenstrasse 8 city: MUENCHEN postcode: 80539 contact info Titolo: Dr. Nome: Sabine Cognome: Koenig Email: send email Telefono: +49 9131 6877500 Fax: +49 9131 6877109	DE (MUENCHEN)	participant	577˙099.95
4	TEL AVIV UNIVERSITY  Organization address address: RAMAT AVIV city: TEL AVIV postcode: 69978 contact info Titolo: Ms. Nome: Lea Cognome: Pais Email: send email Telefono: 97236408774 Fax: 97236409697	IL (TEL AVIV)	participant	473˙367.18
5	UNIVERSIDAD COMPLUTENSE DE MADRID  Organization address address: AVENIDA DE SENECA 2 city: MADRID postcode: 28040 contact info Titolo: Ms. Nome: Maribel Cognome: Rodríguez Villa Email: send email Telefono: 34913946376 Fax: 34913946382	ES (MADRID)	participant	412˙607.20
6	IONICON ANALYTIK GMBH  Organization address address: EDUARD BODEM GASSE 3 city: INNSBRUCK postcode: 6020 contact info Titolo: Dr. Nome: Jens Cognome: Herbig Email: send email Telefono: +43 512 214 800 801 Fax: +43 512 214 800 899	AT (INNSBRUCK)	participant	328˙320.00
7	JLM INNOVATION GMBH  Organization address address: BEETHOVENWEG 41 city: TUEBINGEN postcode: 72076 contact info Titolo: Dr. Nome: Jan Cognome: Mitrovics Email: send email Telefono: +49 7071 940641 Fax: +49 7071 940642	DE (TUEBINGEN)	participant	301˙435.20
8	MICRONIT MICROFLUIDICS BV  Organization address address: COLOSSEUM 15 city: ENSCHEDE postcode: 7521 PV contact info Titolo: Dr. Nome: Marko Cognome: Blom Email: send email Telefono: 31538506850 Fax: 31538506851	NL (ENSCHEDE)	participant	181˙185.01
9	Ionimed Analytik GmbH  Organization address address: Eduard-Bodem-Gasse 3 city: Innsbruck postcode: 6020 contact info Titolo: Dr. Nome: Jens Cognome: Herbig Email: send email Telefono: +43 512 214 800 801 Fax: +43 512 214 800 899	AT (Innsbruck)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The LCAOS project will develop and test a new diagnostic tool, able to detect: (i) the presence of lung cancer (LC), and (ii) an increased risk of a patient developing LC in the future. Diagnostic tests currently available are unsuitable for widespread screening because they are costly, occasionally miss tumours, are not time-efficient, nor free of complications. LCAOS will overcome these problems by using an approach based on volatile biomarkers emitted from cell membranes. A multidisciplinary effort, incorporating nanotechnology, biomedical engineering, medical oncology, and computation strategies, will develop a highly-sensitive, inexpensive, and fast-response, non-invasive, artificial nose (known as, NaNose), building on the coordinator’s earlier success in this area. The NaNose will be able to detect pre-neoplastic volatile biomarkers that indicate an increased genetic risk of LC, and the presence of LC. It has already been established that these biomarkers can be detected either directly from the headspace of the cancer cells or via exhaled breath. LCAOS will: (i) develop arrays of chemically-sensitive field effect transistors (FETs) of non-oxidized, molecule-terminated silicon nanowires (Si NWs); (ii) test the ability of these devices to sense volatile LC biomarkers from in-vitro tissue, and exhaled human breath; (iii) study the signal transduction mechanism of the volatile biomarkers, using pattern recognition; (iv) improve systems to enable the NaNose to distinguish the targeted biomarkers from environmental clutter, using methylation, expression profiling, and genome-wide sequencing; and (v) perform clinical-related studies to assess LC conditions in actual patients & tissues, and in the presence of real-world confounding signals. Validation will be carried out by clinician partners and professional mathematicians and computer scientists. Resources will also be allocated to ensure the commercial potential of the sensor device layout.'

Introduzione (Teaser)

Lung cancer (LC) is a devastating disease whose outcomes are significantly improved with early detection. Scientists are developing an inexpensive artificial nose to analyse exhaled breath and sense increased risk.